Pharmaceutical ProcessingDrug Target Review

Pharmaceutical ProcessingDrug Target Review
Share

Mallinckrodt to acquire InfaCare Pharmaceutical Corporation and stannsoporfin, its proprietary therapy in late-stage development for treatment of newborns at risk for developing severe jaundice. Mallinckrodt plc, a global specialty pharmaceutical company, and InfaCare Pharmaceutical Corporation today announced that they have entered into an...

Onxeo announces positive preclinical proof of concept results confirming AsiDNA activity via systemic administration. Onxeo S.A., a clinical-stage biotechnology company specializing in the development of drugs for the treatment of orphan diseases, in particular in oncology, announced positive preclinical proof of concept results confirming the...

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. Novartis today announced updated results from the ELIANA clinical trial demonstrating CTL019 (tisagenlecleucel) remission rates are maintained at six months in relapsed/refractory (r/r) pediatric and young adult patients with...